Comment on “Lipoprotein(a) reduction with inclisiran, alirocumab, evolocumab, enlicitide, and lerodalcibep: A systematic review and meta-analysis of randomized controlled trials”
Vatsala Gupta, Parag J Ratnakar, Kotina Shridevi, Gaurav, Jeffrin Reneus Paul · 2026
Read Comment on “Lipoprotein(a) reduction with inclisiran, alirocumab, evolocumab, enlicitide, and lerodalcibep: A systematic review and meta-analysis of randomized controlled trials” by Vatsala Gupta, Parag J Ratnakar, Kotina Shridevi, Gaurav, Jeffrin Reneus Paul (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13594998.txt.
Description
Vatsala Gupta and co-authors wrote a 2026 letter commenting on a review of drugs that lower lipoprotein(a), a blood fat linked to heart risk. The review pooled thirty-one trials and concluded that a class of agents lowers the fat to a similar degree. The letter writers question that comparative claim.
They show that several contrast values in the review clash with each other, with point estimates falling outside their own intervals. They also argue that a non-significant difference is not proof of equivalence, above all with high variation and few trials for some drugs. They suggest a corrected table, softer wording, and added checks on uncertainty.
Catalog record
| CREATOR | Vatsala Gupta, Parag J Ratnakar, Kotina Shridevi, Gaurav, Jeffrin Reneus Paul |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 5 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |